ArticleMayo Clinic proceedings. Innovations, quality & outcomes2024
Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Real world experience with faricimab in switched neovascular AMD and evaluation of reloading versus interval matching regimes.Eye (London, England) · 2026Article
- Cost-Effectiveness of the Smaller-Incision New Generation Implantable Miniature Telescope for Late-Stage Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Vision-related quality of life in non-neovascular age-related macular degeneration: a protocol for systematic review and meta-analysis.Eye (London, England) · 2026Review
- CD36-mediated lipid-accumulation in reactive microglia contributes to retinal degeneration via the NLRP3-IL-1β pathway in mice.Nature communications · 2026Article
- Mapping the Reliability-Readability Gap in the Education of Patients With Age-Related Macular Degeneration Across 6 Large Language Models: Comparative Evaluation Study.JMIR medical informatics · 2026Article
- Ergothioneine as a potential protective agent against macular degeneration and other eye disorders.Scientific reports · 2026Article
- Human retinal organoid model of disease-relevant photoreceptor cell death amenable to drug screening.Cell death & disease · 2026Article
- Cataract surgery in the context of age-related macular degeneration: challenges and considerations.Journal of cataract and refractive surgery · 2026Review
- Visible Light Optical Coherence Tomography Reveals Aging at the Retinal Pigment Epithelium-Bruch's Membrane Interface.bioRxiv : the preprint server for biology · 2026Article
- Choroidal Vascular Remodeling and Retinal Response After Aflibercept Loading in Diabetic Macular Edema.Ophthalmology science · 2026Article
- Retinal pigment epithelium pathology in age-related macular degeneration: mitigation with melatonin.Frontiers in medicine · 2026Review
- The Amsler Grid in Everyday Practice: A Review of Its Role and Limitations in Primary Care.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Article
- The gut-retina axis in age-related macular degeneration: immune crosstalk and metabolite production.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Retinal Ischemia: Therapeutic Effects and Mechanisms of Paeoniflorin.International journal of molecular sciences · 2025Article
- Serum RNA Profile Reflects Fluid Status and Atrophic Retinal Changes in Neovascular Age-Related Macular Degeneration.International journal of molecular sciences · 2025Article
- Falls and Fractures in Patients with Geographic Atrophy: A US Claims Data Analysis.Advances in therapy · 2025Article
- Metformin inhibits pathological retinal neovascularization but promotes retinal fibrosis in experimental neovascular age-related macular degeneration.Frontiers in pharmacology · 2025Article
- Modified Zhujing pill regulates RPE cholesterol metabolism and gut microbiota in an age-related macular degeneration mouse model.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the Western world, with a higher prevalence among Europeans and North Americans than that in Africans, Hispanics, and Asians. Advanced AMD is categorized as atrophic (dry) or exudative (wet/neovascular age-related macular degeneration [nAMD]). Dry AMD is characterized by progressive geographic atrophy of the retinal pigment epithelium and outer retinal layers, whereas nAMD is characterized by new vessels that invade the subretinal and/or subretinal pigment epithelium spaces. Existing treatments delay the onset of advanced AMD and reverses vision loss for a couple of years before atrophy usually decreases central visual acuity. We searched PubMed and Medline databases from January 1, 1980, to December 1, 2023, using the following search terms:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.